Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus.

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   AstraZeneca;   Antaros Medical AB;   Bioventure Hub;   43183 Mölndal;   Sweden
Recruiting - verified April 2015

Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes

Conditions:   Diabetic Polyneuropathy;   Diabetes Mellitus;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2;   Diabetes Complications
Intervention:   Other: Exposure: Corneal nerve fibre morphology by the CCM Procedure
Sponsors:   Samuel Lunenfeld Research Institute, Mount Sinai Hospital;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   University of Calgary;   Queensland University of Technology;   University of Michigan;   University of Manchester
Enrolling by invitation - verified February 2015

Family Focused Community Program to Prevent Type 2 Diabetes in Peripubertal Youth

Condition:   Pediatric Obesity
Intervention:   Behavioral: YMCA Family Diabetes Prevention Program (YFDPP)
Sponsor:   University of Arizona
Not yet recruiting - verified April 2015

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Without Control on Metformin Alone

Condition:   Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Glimepiride;   Other: Placebo
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Not yet recruiting - verified April 2015

Glucose Metabolism, Muscle Mass/Function and Inflammation in the Elderly

Conditions:   Sarcopenia;   Diabetes Mellitus
Intervention:  
Sponsors:   Catholic University of the Sacred Heart;   University of Rome Tor Vergata;   Fondazione Roma
Not yet recruiting - verified April 2015

Study to Weigh the Effect of Exercise Training on BONE (SWEET-BONE) Quality and Strength in Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Other: supervised exercise training
Sponsors:   Metabolic Fitness Association, Italy;   University of Roma La Sapienza;   S. Andrea Hospital
Not yet recruiting - verified April 2015

Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects

Conditions:   Type 2 Diabetes;   Coronary Artery Disease
Intervention:   Drug: Icosapent ethyl
Sponsor:   Brigham and Women's Hospital
Not yet recruiting - verified April 2015

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine;   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified April 2015

Short Term Intermittent Fasting and Insulin Resistance

Conditions:   Diabetes Mellitus;   Non-alcoholic Fatty Liver Disease;   Metabolic Syndrome;   Obesity
Interventions:   Behavioral: Intermittent fasting;   Other: Time control
Sponsors:   University of Copenhagen;   Herlev Hospital
Recruiting - verified April 2015

Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Dapagliflozin
Sponsors:   Seoul National University Hospital;   AstraZeneca
Recruiting - verified April 2015

Lifestyle and Glucose Lowering Medication in T2DM

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: U-TURN;   Behavioral: Standard care
Sponsors:   Rigshospitalet, Denmark;   TRYG Foundation
Recruiting - verified April 2015

The Early Warning System for the Diabetic Encephalopathy

Conditions:   Diabetes Mellitus Type 2;   Mild Cognitive Impairment;   Metabolic Syndrome X
Intervention:  
Sponsor:   Tang-Du Hospital
Not yet recruiting - verified April 2015

A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Device: PaQ® Insulin Delivery Device;   Drug: Insulin, Asp(B28)-
Sponsor:   CeQur Corporation
Recruiting - verified April 2015

The Impact of Resistance Training on Type 2 Diabetes Patients.

Condition:   Diabetes
Interventions:   Other: Resistance training;   Behavioral: Lifestyle counselling
Sponsor:   Huashan Hospital
Recruiting - verified April 2015

Metabolic and Immune System Responses to a Mixed Meal

Condition:   Inflammation
Intervention:   Other: Consumption of a mixed meal
Sponsors:   University of Bath;   Biotechnology and Biological Sciences Research Council;   Unilever R&D
Completed - verified April 2015

Add Glucokinase Activator to Target A1c

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: TTP399 400 mg;   Drug: TTP399 800 mg;   Drug: Sitagliptin 100 mg;   Drug: Placebo
Sponsor:   TransTech Pharma, LLC.
Recruiting - verified April 2015

Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Pioglitazone;   Drug: Glimepiride
Sponsor:   Pusan National University Hospital
Recruiting - verified April 2015

A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: AR-C165395XX;   Other: Placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified April 2015

Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional

Condition:   Type 2 Diabetes Mellitus
Intervention:   Device: Abbott Sensor Based Glucose Monitoring System-Professional
Sponsor:   Abbott Diabetes Care
Recruiting - verified April 2015

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine U300 HOE901;   Drug: Insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified April 2015

Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population

Condition:   Type 2 Diabetes
Intervention:  
Sponsors:   Weill Medical College of Cornell University;   Hamad Medical Corporation;   Weill Cornell Medical College in Qatar
Not yet recruiting - verified April 2015

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

Conditions:   Overweight;   Obesity
Interventions:   Device: Gelesis100;   Device: placebo
Sponsor:   Gelesis, Inc.
Recruiting - verified April 2015

An Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes

Condition:   Hypertension
Intervention:  
Sponsors:   Abbott;   Monitor Medikal Araştırma ve Danışmanlık Tic.Ltd.Şti (MonitorCRO)
Recruiting - verified April 2015

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: insulin degludec/liraglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified April 2015

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR342434;   Drug: insulin lispro;   Drug: insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified April 2015

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Sitagliptin;   Drug: Placebo matching with Saxagliptin;   Drug: Placebo matching with Dapagliflozin;   Drug: Placebo matching with Sitagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified February 2015

Physical Activity and Participation

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Counseling
Sponsor:   Department of Veterans Affairs
Not yet recruiting - verified April 2015

A Phase 2 Dose-finding Study of TAK-272 in Patients With Type 2 Diabetes Mellitus and Microalbuminuria

Condition:   Type 2 Diabetes Mellitus and Microalbuminuria
Interventions:   Drug: TAK-272 tablets;   Drug: Placebo tablets;   Drug: Candesartan cilexetil tablets
Sponsor:   Takeda
Recruiting - verified April 2015

Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Sitagliptin;   Drug: Placebo to Ertugliflozin;   Drug: Placebo to Sitagliptin;   Drug: Glimepiride
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified April 2015

Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: 10mg DS-8500a tablet;   Drug: 75mg DS-8500a tablet;   Drug: placebo
Sponsor:   Daiichi Sankyo Co., Ltd.
Completed - verified April 2015

A Phase 1 Single Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2015

TOFO Insulin Combination Trial

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: TOFOGLIFLOZIN CSG452;   Drug: insulin;   Drug: placebo
Sponsors:   Sanofi;   Kowa Company, Ltd.
Recruiting - verified April 2015

Effect of Personalized Feedback Report and Peer Support on Diabetes

Condition:   Diabetes
Interventions:   Behavioral: Peer support;   Behavioral: Personalized feedback report
Sponsor:   Chinese University of Hong Kong
Recruiting - verified April 2015

Making Ramadhan Fasting a Safer Experience With Technology Study

Condition:   Diabetes Mellitus, Non-Insulin-Dependent
Intervention:   Device: Telemedicine
Sponsors:   Monash University;   SEGi University
Recruiting - verified April 2015

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type II
Interventions:   Drug: Placebo;   Drug: PF-06291874;   Drug: PF-06291874;   Drug: PF-06291874;   Drug: PF-06291874
Sponsor:   Pfizer
Completed - verified April 2015

A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Intervention:   Device: PaQ® Insulin Delivery Device
Sponsor:   CeQur Corporation
Terminated - verified April 2015

Pyridorin in Diabetic Nephropathy

Conditions:   Diabetic Nephropathy;   Diabetic Kidney Disease
Interventions:   Drug: Pyridorin;   Drug: Placebo
Sponsors:   NephroGenex, Inc.;   Collaborative Study Group (CSG);   Medpace, Inc.
Recruiting - verified April 2015

A Study to Compare the Effect of Double Doses of Long-acting Insulin Therapies in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin Peglispro;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2015

Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Boehringer Ingelheim
Completed - verified April 2015

The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy

Conditions:   Diabetes Mellitus;   Type I Diabetes;   Type II Diabetes;   Diabetic Peripheral Neuropathy;   Chronic Pain
Intervention:   Behavioral: Mindfulness Based Stress Reduction
Sponsors:   Ottawa Hospital Research Institute;   Canadian Diabetes Association
Recruiting - verified April 2015

Regulation of Endogenous Glucose Production by Brain Insulin Action

Condition:   Insulin Resistance, Diabetes
Intervention:   Drug: Intranasal insulin
Sponsor:   University Health Network, Toronto
Completed - verified April 2015

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Type 2 Diabetes Mellitus
Interventions:   Drug: insulin 287;   Drug: insulin degludec;   Drug: placebo;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified April 2015

Can Vitamin D Supplementation Prevent Type 2 Diabetes?

Condition:   Type 2 Diabetes Mellitus
Interventions:   Dietary Supplement: Vitamin D;   Dietary Supplement: Placebo
Sponsors:   Monash University;   University of Victoria;   University of Auckland, New Zealand
Recruiting - verified April 2015

Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Ertugliflozin 15 mg
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Completed - verified April 2015

Ertugliflozin and Sitagliptin Co-administration Factorial Study (MK-8835-005)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Matching Placebo to Ertugliflozin 5 mg;   Drug: Matching Placebo to Ertugliflozin 10 mg;   Drug: Matching Placebo to sitagliptin 100 mg;   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Sitagliptin 100 mg;   Drug: Metformin >= 1500 mg/day;   Biological: Insulin Glargine Rescue Medication;   Drug: Glimepiride Rescue Medication
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified April 2015

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified April 2015

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Glimepiride;   Drug: Metformin;   Drug: Pioglitazone;   Drug: Acarbose;   Drug: Linagliptin;   Drug: Sitagliptin;   Drug: Liraglutide;   Drug: Insulin Glargine;   Drug: Exenatide once weekly (QW);   Drug: Exenatide twice daily (BID)
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2015

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified April 2015

A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified April 2015

Physical Activity and Obesity

Conditions:   Obesity;   Prediabetic State;   Sedentary Lifestyle
Intervention:   Behavioral: High Activity
Sponsor:   Oregon Health and Science University
Recruiting - verified April 2015

The Efficacy of Bariatric Surgery Compared to Medical Therapy in Controlling Type2 Diabetes Mellitus in Patients With Non Morbid Obesity.

Conditions:   Overweight;   Diabetes Type 2
Interventions:   Procedure: Laparoscopic Sleeve Gastrectomy;   Procedure: Laparoscopic Roux-en-Y Gastric Bypass;   Drug: Advanced Medical Therapy
Sponsor:   Hadassah Medical Organization
Recruiting - verified February 2015

Pathobiology and Reversibility of Prediabetes in a Biracial Cohort

Conditions:   Prediabetes;   Type 2 Diabetes;   Obesity
Intervention:   Behavioral: Intensive Lifestyle Intervention (ILI)
Sponsors:   University of Tennessee;   National Institutes of Health (NIH)
Enrolling by invitation - verified April 2015

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2015

Arginase Inhibition in Ischemia-reperfusion Injury

Conditions:   Coronary Artery Disease;   Type 2 Diabetes Mellitus
Interventions:   Drug: N-hydroxy-nor-arginine;   Drug: NaCl
Sponsor:   Karolinska Institutet
Completed - verified April 2015

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 50 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2015

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 90 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Recruiting - verified April 2015

Alogliptin/Pioglitazone (Liovel) Liovel Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Alogliptin/pioglitazone
Sponsor:   Takeda
Completed - verified April 2015

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified April 2015

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Condition:   Li-Fraumeni Syndrome
Intervention:   Drug: Metformin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2014

Evaluation of the Ottawa Model for Smoking Cessation in Diabetes Education Programs

Conditions:   Pre-diabetic;   Diabetic Type II Mellitus
Intervention:   Behavioral: Ottawa Model for Smoking Cessation
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting - verified January 2015

Southeastern Diabetes Initiative Clinical Intervention

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Extension of Care
Sponsors:   Duke University;   Centers for Medicare and Medicaid Services;   Bristol-Myers Squibb
Active, not recruiting - verified April 2015

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified April 2015

Acute Effects of Moderate Versus High Intensity Exercise on Insulin Sensitivity in Gestational Diabetes Mellitus

Condition:   Diabetes, Gestational
Intervention:   Behavioral: exercise
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital
Recruiting - verified April 2015

Metabolic Clock Genes During Fasting and After Food Intake in Type 2 Diabetics

Condition:   Type 2 Diabetes
Interventions:   Other: No Breakfast (NoB);   Other: Yes Breakfast  (YesB)
Sponsor:   Tel Aviv University
Recruiting - verified April 2015

Effects of Whey Protein in Type 2 Diabetics

Condition:   Type 2 Diabetes
Interventions:   Dietary Supplement: Whey Protein (WPC);   Dietary Supplement: WPC + Alpha-lactalbumin (Alpha);   Dietary Supplement: Gluten protein (GLT)
Sponsor:   Tel Aviv University
Recruiting - verified April 2015

Oklahoma Native American Women's Osteoporosis Screening Study

Condition:   Osteoporosis
Intervention:  
Sponsor:   Oklahoma State University
Active, not recruiting - verified April 2015

Walnut Consumption, Endothelial Function, and Biomarkers

Conditions:   Coronary Heart Disease;   Type 2 Diabetes
Intervention:   Other: Once ounce per day of walnuts
Sponsor:   Brigham and Women's Hospital
Active, not recruiting - verified April 2015

A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin detemir;   Drug: insulin detemir
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified April 2015

Clinical Trial of Efficiency and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: Subetta;   Drug: Placebo
Sponsor:   Materia Medica Holding
Recruiting - verified May 2013

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2014

A Study of the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

Condition:   Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo to MK-3102;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2015

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 300 mg;   Drug: Metformin XR
Sponsor:   Janssen Research & Development, LLC
Completed - verified April 2015

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: lixisenatide (AVE0010);   Drug: placebo
Sponsor:   Sanofi
Completed - verified April 2015

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Comparative Effectiveness of Glycemia-lowering Medications
Interventions:   Drug: Sulfonylurea (glimepiride);   Drug: DPP-4 inhibitor (sitagliptin);   Drug: GLP-1 receptor agonist (liraglutide);   Drug: Insulin (glargine)
Sponsors:   GRADE Study Group;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Heart, Lung, and Blood Institute (NHLBI);   Becton, Dickinson and Company;   Bristol-Myers Squibb;   Merck Sharp & Dohme Corp.;   Novo Nordisk A/S;   Hoffmann-La Roche;   Sanofi
Recruiting - verified March 2015

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine;   Biological: Background insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2015

Validation of an RLIP76 Assay in Humans

Condition:   Type 2 Diabetes
Intervention:   Other: Blood Draw
Sponsor:   City of Hope Medical Center
Recruiting - verified April 2015

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: BMS-813160;   Drug: Placebo matching with BMS-813160
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified April 2015

Screening and Understanding of the Pre-diabetes: DECODIAB

Condition:   Pre-diabetes
Intervention:   Other: Biopsies of muscular and fat tissue
Sponsor:   Nantes University Hospital
Active, not recruiting - verified April 2015

Better Diabetes Control, Quality - Educate to Achieve Compliance

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified April 2015

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: HOE901-U300 (new formulation of insulin glargine);   Drug: Lantus (insulin glargine)
Sponsor:   Sanofi
Completed - verified April 2015

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Placebo matching with Dapagliflozin;   Drug: Saxagliptin;   Drug: Metformin immediate release (IR)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Completed - verified October 2014

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: Dulaglutide;   Drug: Insulin glargine;   Drug: Insulin lispro
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2015

Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer

Condition:   Prostate Cancer
Interventions:   Drug: Placebo and Castration;   Drug: Metformin and Castration
Sponsor:   Devalingam Mahalingam
Recruiting - verified March 2015

Italian Diabetes and Exercise Study 2

Condition:   Type 2 Diabetes
Intervention:   Behavioral: Theoretical & practical exercise counseling
Sponsors:   Metabolic Fitness Association, Italy;   University of Roma La Sapienza
Active, not recruiting - verified April 2015

The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes

Conditions:   Coronary Artery Disease;   Diabetes Mellitus, Type 2
Interventions:   Drug: Liraglutide;   Drug: Placebo
Sponsor:   Haugaard, Steen Bendix, M.D., DMSc
Active, not recruiting - verified April 2015

Fibrosis a New Pathological Actor in Adipose Tissue

Conditions:   Obesity;   Metabolic Diseases;   Fibrosis;   Body Weight
Intervention:   Procedure: biopsy
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified April 2015

Study of Offspring of Women With Type 1 Diabetes

Condition:   Type 1 Diabetes
Intervention:  
Sponsors:   Odense University Hospital;   University of Copenhagen;   Department of Gynaecology and Obstetrics, Rigshospitalet, Copenhagen;   Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark;   University of Southern Denmark;   University of Aarhus;   Aarhus University Hospital
Active, not recruiting - verified April 2015

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2015

Treatment of Diabetes After Gastric Bypass With Sitagliptin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin phosphate;   Other: Placebo
Sponsors:   Blandine Laferrere;   Merck Sharp & Dohme Corp.
Recruiting - verified April 2015

Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria

Conditions:   Diabetes;   Hypertensive Disease
Interventions:   Drug: Renin-angiotensin system blockers;   Drug: non-renin angiotensin system blockers
Sponsor:   Hospital Authority, Hong Kong
Recruiting - verified April 2015

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: HOE901-U300 (new formulation of insulin glargine);   Drug: Lantus (insulin glargine)
Sponsor:   Sanofi
Completed - verified April 2015

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Lantus (Insulin glargine);   Drug: HOE901-U300 (new formulation of insulin glargine)
Sponsor:   Sanofi
Completed - verified April 2015

Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

Condition:   Diabetes Mellitus, Type II
Interventions:   Drug: Liraglutide;   Drug: Insulin
Sponsor:   Mountain Diabetes and Endocrine Center
Completed - verified November 2013

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2015

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo matching with Saxagliptin;   Drug: Metformin IR;   Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2014

Effect of Vitamin D Supplementation on Hemoglobin A1c

Conditions:   Diabetes Mellitus;   Vitamin D Deficiency
Interventions:   Dietary Supplement: Vitamin D;   Dietary Supplement: Vitamin D
Sponsor:   Genesys Regional Medical Center
Completed - verified April 2015

Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin for Treatment of Type 2 DM.

Condition:   Diabetes
Interventions:   Drug: Group 1: Metformin;   Dietary Supplement: Group 2: Cinnamon Bark;   Dietary Supplement: Group 3: Cinnulin PF
Sponsor:   Mike O'Callaghan Federal Hospital
Recruiting - verified April 2015

Contribution Of Nuclear Magnetic Resonance Imaging In The Study Of Diabetic Cardiomyopathy

Conditions:   Diabetic;   Cardiomyopathy
Interventions:   Other: NUCLEAR MAGNETIC RESONANCE IMAGING;   Other: NUCLEAR MAGNETIC RESONANCE IMAGING
Sponsor:   Assistance Publique Hopitaux De Marseille
Recruiting - verified April 2015

A Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking Nutralin

Condition:   Diabetes
Intervention:   Dietary Supplement: Nutralin
Sponsor:   Avera McKennan Hospital & University Health Center
Withdrawn - verified April 2015

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo (Saxagliptin);   Drug: Metformin IR;   Drug: Placebo (Metformin);   Drug: Metformin (Active Rescue)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2014

Estimation of Glomerular Filtration Rate (GFR) in Patients With Type 2 Diabetes Mellitus.

Conditions:   Diabetes Mellitus;   Diabetic Nephropathy
Intervention:  
Sponsor:   AHEPA University Hospital
Recruiting - verified April 2015

A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)

Condition:   Type 2 Diabetes Mellitus (T2DM)
Intervention:   Drug: Ertugliflozin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Completed - verified April 2015

Effects of Physical Exercise in Type 2 Diabetics

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Physical exercise
Sponsor:   University Hospital, Strasbourg, France
Recruiting - verified April 2015

Effects Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)

Conditions:   Diabetes Mellitus, Type 2;   Adult
Interventions:   Drug: Ertugliflozin 2 mg single dose;   Drug: Ertugliflozin 2 mg split into twice daily;   Drug: Ertugliflozin 4 mg single dose;   Drug: Ertugliflozin 4 mg split into twice daily;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Completed - verified April 2015

Metabolic Surgery Versus Medical Management for Resolution of Type II Diabetes

Conditions:   Obesity;   Type 2 Diabetes Mellitus
Interventions:   Other: Laboratory evaluations, sleep study;   Other: Best Medical Management;   Procedure: Roux-en-Y gastric bypass surgery
Sponsors:   David Bradley MD;   Covidien
Completed - verified April 2015

Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study

Conditions:   Obesity;   Diabetes Mellitus, Type 2;   Abnormal Glucose Metabolism;   Type 2 Diabetes
Intervention:   Behavioral: Assignment of a Lay Patient Partner
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified April 2015

A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo to Ertugliflozin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Completed - verified April 2015

Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia

Condition:   Metabolic Syndrome
Interventions:   Drug: Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan;   Other: As selected by community physician
Sponsor:   North Shore Long Island Jewish Health System
Terminated - verified November 2011

Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

Condition:   Type 2 Diabetes
Intervention:   Drug: exenatide
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified March 2015

Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)

Conditions:   Hypercholesterolemia;   Atherosclerosis
Interventions:   Drug: Ezetimibe;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Merck Frosst Canada Ltd.
Terminated - verified April 2015

Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)

Condition:   Small for Gestational Age
Interventions:   Drug: rhGH (Norditropine SimpleXx®);   Drug: rhGH norditropine simple Xx
Sponsor:   Assistance Publique - Hôpitaux de Paris
Terminated - verified April 2014

Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: rosiglitazone maleate/metformin hydrochloride
Sponsor:   GlaxoSmithKline
Completed - verified May 2013

A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.

Conditions:   Heart Diseases;   Diabetes Mellitus, Type 2
Intervention:   Behavioral: Patient adherence to national educational guidelines.
Sponsor:   Pfizer
Completed - verified April 2015

Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: denagliptin (GW823093)
Sponsor:   GlaxoSmithKline
Withdrawn - verified April 2015

GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients

Conditions:   Diabetes Mellitus, Type 2;   Non-Insulin-Dependent Diabetes Mellitus
Interventions:   Drug: GSK189075 oral tablets;   Drug: GW869682 oral tablets
Sponsor:   GlaxoSmithKline
Completed - verified April 2015

Pilot Study of Vedic Medicine for Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Vedic Medicine;   Behavioral: Vedic Medicine
Sponsor:   National Center for Complementary and Integrative Health (NCCIH)
Completed - verified April 2015

Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension

Condition:   Hypertension
Interventions:   Drug: carvedilol;   Drug: metoprolol
Sponsor:   GlaxoSmithKline
Completed - verified June 2012

Get CardioSmart

You're Invited